z-logo
open-access-imgOpen Access
Comparison between a liquid chromatography‐tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations
Author(s) -
Dailly Eric,
Deslandes G.,
Hourmant M.,
Petit T.,
Renaud C.,
Treilhaud M.,
Jolliet P.
Publication year - 2008
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20258
Subject(s) - fluorescence polarization immunoassay , everolimus , liquid chromatography–mass spectrometry , chromatography , mass spectrometry , immunoassay , heart transplantation , chemistry , transplantation , tandem mass spectrometry , medicine , immunology , antibody
Various methods [fluorescent polarization immunoassay (FPIA) and liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) assay] are used for therapeutic drug monitoring of everolimus. The aim of this study is to compare these assays in renal and heart transplantation. The correlation between results was investigated by linear regression in 44 patients (24 heart recipients and 20 renal recipients—137 samples). The comparison between assays was performed by a paired t ‐test. A highly significant correlation was found between FPIA and LC‐MS/MS in heart and renal recipients [FPIA=0.851 × LC‐MS/MS+1.773 r 2 =0.8738 ( P <0.001)]. Paired t ‐tests did not show a significant difference between everolimus whole blood concentrations in the populations of heart and renal recipients or heart recipients or renal recipients. FPIA and LC‐MS/MS assays gave consistent overall results although some significant differences were observed in some samples between these methods indicating that FPIA assay has limitations that deserve further investigations. J. Clin. Lab. Anal. 22:282‐285, 2008. © 2008 Wiley‐Liss, Inc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here